Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report

References

• Che Y, Luo Z, Cao Y, Sun N, Xue Q, He J. PD-L1 predicts chemotherapy resistance in large-cell neuroendocrine carcinoma. Br J Surg. 2023;110:749–5. doi:10.1093/bjs/znac335. PMID: 36205121.
   PubMed Web of Science ®Google Scholar
• Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Sig Transduct Target Ther. 2022;7:331. doi:10.1038/s41392-022-01136-2. PMID: 36123348.
   PubMed Web of Science ®Google Scholar
• Song L, Zhou F, Xu T, Zeng L, Xia Q, Wang Z, Deng L, Li Y, Qin H, Yan H, et al. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study. BMC Cancer. 2023;23:443. doi:10.1186/s12885-023-10952-w. PMID: 37189075.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, Ramaiya NH. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e211136. doi:10.1001/jamanetworkopen.2021.1136. PMID: 33760090.
   PubMed Web of Science ®Google Scholar
• Long Y, Yang W, Bai Y, Tao H, Zhang F, Wang L, Yang B, Huang D, Han X, Hu Y. Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study. Cancer Cell Int. 2023;23:224. doi:10.1186/s12935-023-03070-x. PMID: 37777758.
   PubMed Web of Science ®Google Scholar
• Gong C, Zhang W, Sun Y, Shou J, Jiang Z, Liu T, Wang S, Liu J, Sun Y, Zhou A. Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. iScience. 2023;26:106720. doi:10.1016/j.isci.2023.106720. PMID: 37255657.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8. doi:10.1158/1078-0432.Ccr-16-1741. PMID: 27827313.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793–802. doi:10.1007/s10120-018-00922-8. PMID: 30627987.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang F, Zhong M, Yarden Y, Fu L. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020;19:81. doi:10.1186/s12943-020-01200-x. PMID: 32359357.
   PubMed Web of Science ®Google Scholar
• Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, et al. MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and Mucosal Melanoma. Cancers Basel. 2020;12:540. doi:10.3390/cancers12030540. PMID: 32110946.
   PubMed Web of Science ®Google Scholar
• Li Y, Shi X, Mao B, Wang L, Wu L, Li J, Jiao S. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8(+) T cell infiltration in Chinese lung large cell neuroendocrine carcinoma. Lung Cancer. 2022;166:161–9. doi:10.1016/j.lungcan.2022.01.007. PMID: 35287068.
   PubMed Web of Science ®Google Scholar
• Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023;41:304–22.e7. doi:10.1016/j.ccell.2022.12.008. PMID: 36638784.
   PubMed Web of Science ®Google Scholar
• Malgundkar SH, Burney I, Al Moundhri M, Al Kalbani M, Lakhtakia R, Okamoto A, Tamimi Y. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer. BMC Cancer. 2020;20:374. doi:10.1186/s12885-020-06900-7. PMID: 32366234.
   PubMed Web of Science ®Google Scholar
• Cai J, Feng D, Hu L, Chen H, Yang G, Cai Q, Gao C, Wei D. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling. Br J Cancer. 2015;113:1720–9. doi:10.1038/bjc.2015.367. PMID: 26633557.
   PubMed Web of Science ®Google Scholar
• Tang T, Guo C, Xia T, Zhang R, Zen K, Pan Y, Jin L. LncCCAT1 promotes breast cancer stem cell function through activating WNT/β-catenin signaling. Theranostics. 2019;9:7384–402. doi:10.7150/thno.37892. PMID: 31695775.
   PubMed Web of Science ®Google Scholar
• Li N, Kong M, Zeng S, Hao C, Li M, Li L, Xu Z, Zhu M, Xu Y. Brahma related gene 1 (Brg1) contributes to liver regeneration by epigenetically activating the Wnt/β-catenin pathway in mice. FASEB J. 2019;33:327–338. doi:10.1096/fj.201800197R. PMID: 30001167.
   PubMed Web of Science ®Google Scholar
• Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, et al. Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. bioRxiv. 2023. doi:10.1101/2023.08.08.552544. PMID: 37609261.
   PubMedGoogle Scholar
• Marín-Rubio JL, Raote I, Inns J, Dobson-Stone C, Rajan N. CYLD in health and disease. Dis Model Mech. 2023;16. doi:10.1242/dmm.050093. PMID: 37387450.
   PubMed Web of Science ®Google Scholar
• Cui Z, Kang H, Grandis JR, Johnson DE. CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers. Mol Cancer Res. 2021;19:14–24. doi:10.1158/1541-7786.Mcr-20-0565. PMID: 32883697.
   PubMed Web of Science ®Google Scholar
• Loesch R, Caruso S, Paradis V, Godard C, Gougelet A, Renault G, Picard S, Tanaka I, Renoux-Martin Y, Perret C, et al. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. J Hepatol. 2022;77:424–35. doi:10.1016/j.jhep.2022.02.023. PMID: 35257829.
   PubMed Web of Science ®Google Scholar
• Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in Hepatocellular Carcinoma. Cancer Discov. 2019;9:1124–41. doi:10.1158/2159-8290.Cd-19-0074. PMID: 31186238.
   PubMed Web of Science ®Google Scholar
• Fang CH, Lin YT, Liang CM, Liang SM. A novel c-kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling. J Biomed Sci. 2020;27:42. doi:10.1186/s12929-020-00638-x. PMID: 32169072.
   PubMed Web of Science ®Google Scholar
• Li Q, Lai Q, He C, Fang Y, Yan Q, Zhang Y, Wang X, Gu C, Wang Y, Ye L, et al. RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer. J Exp Clin Cancer Res. 2019;38:334. doi:10.1186/s13046-019-1330-9. PMID: 31370857.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, et al. Predictive nomogram for hyperprogressive disease during anti-PD-1/PD-L1 treatment in patients with advanced non-small cell lung cancer. Immunotargets Ther. 2023;12:1–16. doi:10.2147/itt.S373866. PMID: 36632330.
   PubMed Web of Science ®Google Scholar
• Andrini E, Marchese PV, De Biase D, Mosconi C, Siepe G, Panzuto F, Ardizzoni A, Campana D, Lamberti G. Large cell neuroendocrine carcinoma of the lung: current understanding and challenges. J Clin Med. 2022;11:11. doi:10.3390/jcm11051461. PMID: 35268551.
   Web of Science ®Google Scholar
• Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, et al. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. J Immunother Cancer. 2022;10:e004273. doi:10.1136/jitc-2021-004273. PMID: 35383114.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu J, Luo H, Meng X, Chen M, Zhu D. Wnt signaling pathway in cancer immunotherapy. Cancer Lett. 2022;525:84–96. doi:10.1016/j.canlet.2021.10.034. PMID: 34740608.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074–83. doi:10.1158/1078-0432.Ccr-18-1942. PMID: 30635339.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116–26. doi:10.1158/1078-0432.Ccr-18-2293. PMID: 30373752.
   PubMed Web of Science ®Google Scholar
• Wei Z, Zhang Y. Immune cells in hyperprogressive disease under immune checkpoint-based immunotherapy. Cells. 2022;11:11. doi:10.3390/cells11111758. PMID: 35681453.
   Web of Science ®Google Scholar
• Feng D, Guan Y, Liu M, He S, Zhao W, Yin B, Liang J, Li Y, Wang Y, Wang J. Excellent response to atezolizumab after clinically defined hyperprogression upon previous treatment with pembrolizumab in metastatic triple-negative breast cancer: a case report and review of the literature. Front Immunol. 2021;12:608292. doi:10.3389/fimmu.2021.608292. PMID: 34135884.
   PubMed Web of Science ®Google Scholar